Erik Swain

MUNICH — Remote exercise-based cardiac rehabilitation did not increase participation compared with center-based cardiac rehab in patients with heart attack, according to findings presented at the European Society of Cardiology Congress.However, patients with the option to use a remote exercise-based program had just as much improvement in physical capacity as those who had to use a

MUNICH — A digital strategy involving an emailed letter inviting patients with heart failure to be evaluated by a specialist for SGLT2 inhibitor therapy dramatically increased SGLT2 inhibitor prescriptions, researchers reported. For the EMAIL-HF registry-based randomized trial, presented at the European Society of Cardiology Congress, researchers identified all patients with HF in the

MUNICH — In patients with left-sided infective endocarditis, a response-tailored antibiotic strategy conferred more time alive without antibiotic therapy compared with standard duration therapy, new data show. For the POET II trial, presented at the European Society of Cardiology Congress and simultaneously published in The New England Journal of Medicine, the researchers randomly assigned

CHICAGO — Major diabetic foot complications were more common in patients with type 2 diabetes treated with SGLT2 inhibitors than those treated with GLP-1 receptor agonists, researchers reported at ENDO 2026.However, new-onset diabetic peripheral neuropathy was lower in patients taking SGLT2 inhibitors compared with those taking GLP-1s, according to the researchers.

A novel NLRP3 inhibitor reduced high-sensitivity C-reactive protein and other inflammatory biomarkers in patients at high inflammatory risk, according to the results of a trial presented at the European Atherosclerosis Society Congress. The NLRP3 inhibitor, ruvonoflast (NodThera), “is designed to directly inhibit activation of the NLRP3 inflammasome in multiple clinically relevant cell

NEW ORLEANS — In adults with insulin-treated type 2 diabetes, an automated insulin delivery system conferred lower HbA1c and improved time in range at 13 weeks, researchers reported at the American Diabetes Association Scientific Sessions. As Healio previously reported, the system (twiist, Sequel) received FDA clearance in 2024 for treatment of patients with type 1 diabetes aged 6

A novel pulsed field ablation technology was safe and prevented atrial arrhythmia recurrence in most patients with paroxysmal atrial fibrillation at 1 year, according to a first-in-human study presented at Heart Rhythm 2026. The circular nanosecond pulsed field ablation catheter (CellFX nsPFA 360, Pulse Biosciences) delivers nanosecond pulses as opposed to the microsecond pulses delivered by

The Apple Watch captured true arrhythmia events in children more frequently than standard patch monitoring, according to results of the Pediatric Apple Watch Study presented at Heart Rhythm 2026. “After the Apple Heart Study was published, we started to see a lot of pediatric patients come into our pediatric cardiology clinics having used their Apple Watch for arrhythmia detection,”

People taking GLP-1s had reduced risk for atrial fibrillation, regardless of whether they lost weight or how much they lost, according to findings presented at Heart Rhythm 2026. “We were prompted to undertake this study by some encouraging data that ... GLP-1 receptor agonists seem to have a favorable effect on reducing the incidence of atrial fibrillation, particularly in patients with

People reporting a high level of loneliness, but not those with social isolation, had elevated risk for developing valvular heart disease, according to the results of a prospective cohort study. “Degenerative valvular heart disease is becoming more common as populations age,” Zhaowei Zhu, MD, PhD, associate professor of cardiovascular medicine at the Second Xiangya Hospital, Central